A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Status:
Recruiting
Trial end date:
2026-02-15
Target enrollment:
Participant gender:
Summary
This research study is studying cytokine induced memory-like natural killer (CIML NK) cells
plus IL-2 in adult patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell
transplantation (haplo-HCT). This study will also study CIML NK cell infusion combined with
IL-2 in pediatric patients (12 years of age or older) with AML, MDS, JMML who relapse after
stem cell transplantation using HLA-matched related donor or related donor haploidentical
stem cells.